Ensysce Historical Balance Sheet
| ENSC Stock | USD 3.20 0.30 8.57% |
Trend analysis of Ensysce Biosciences balance sheet accounts such as Total Stockholder Equity of 3.9 T or Cash of 3.4 M provides information on Ensysce Biosciences' total assets, liabilities, and equity, which is the actual value of Ensysce Biosciences to its prevalent stockholders. By breaking down trends over time using Ensysce Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Ensysce Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ensysce Biosciences is a good buy for the upcoming year.
Ensysce Biosciences Inventory |
|
Ensysce |
About Ensysce Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Ensysce Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Ensysce Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Ensysce Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Ensysce currently owns. An asset can also be divided into two categories, current and non-current.
Ensysce Biosciences Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Ensysce Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Ensysce Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Ensysce Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Ensysce Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Ensysce Biosciences balance sheet. This account contains Ensysce Biosciences investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Ensysce Biosciences fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most accounts from Ensysce Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Ensysce Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.At present, Ensysce Biosciences' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash And Short Term Investments is expected to grow to about 3.7 T, whereas Total Assets are forecasted to decline to about 5.3 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Total Current Liabilities | 9.5M | 3.3M | 2.2T | 2.3T | Total Assets | 5.9M | 2.7M | 5.6M | 5.3M |
Ensysce Biosciences balance sheet Correlations
Click cells to compare fundamentals
Ensysce Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ensysce Biosciences balance sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 351.8K | 16.4M | 5.9M | 2.7M | 5.6M | 5.3M | |
| Total Current Liabilities | 7.0M | 16.5M | 9.5M | 3.3M | 2.2T | 2.3T | |
| Total Stockholder Equity | (6.4M) | (8.2M) | (4.0M) | (322.9K) | 3.7T | 3.9T | |
| Retained Earnings | (56.0M) | (85.8M) | (110.9M) | (121.6M) | (129.5T) | (123.1T) | |
| Cash | 194.2K | 12.3M | 3.1M | 1.1M | 3.5M | 3.4M | |
| Other Assets | 3.8K | 754.8K | 585.9K | (5.3T) | (4.8T) | (4.6T) | |
| Cash And Short Term Investments | 194.2K | 12.3M | 3.1M | 1.1M | 3.5T | 3.7T | |
| Common Stock Shares Outstanding | 68.8K | 84.0K | 179.9K | 2.3M | 1.7M | 1.7M | |
| Short Term Investments | 202.9M | 195.3M | 12.6M | 3.5T | 4.0T | 4.2T | |
| Long Term Debt Total | 566.3K | 791.3K | 4.4M | 140.2K | 161.2K | 153.1K | |
| Liabilities And Stockholders Equity | 351.8K | 16.4M | 5.9M | 2.7M | 5.6M | 5.3M | |
| Capital Surpluse | 2.9M | 2.5M | 78.0M | 107.2M | 123.3M | 129.5M | |
| Total Liab | 7.0M | 24.6M | 9.9M | 3.4M | 10.1B | 10.6B | |
| Total Current Assets | 347.9K | 15.7M | 5.3M | 2.3M | 5.3T | 5.6T | |
| Short Term Debt | 4.3M | 12.7M | 4.3M | 854.7K | 301.7B | 316.7B | |
| Common Stock | 1.6K | 2.5K | 642.0 | 315.0 | 136.0 | 129.2 | |
| Other Current Liab | 856.0K | 3.4M | 2.3M | 542.3K | 1.9T | 2.0T | |
| Net Debt | 4.1M | 483.4K | 1.3M | (268.9K) | (3.2T) | (3.0T) | |
| Accounts Payable | 1.7M | 301.1K | 2.9M | 1.9M | 1.4M | 1.5M | |
| Non Current Assets Total | 3.9K | 754.8K | 585.9K | 419.2K | 252.6K | 239.9K | |
| Non Currrent Assets Other | 3.8K | (24.7B) | 558.7K | 419.2K | 252.6K | 265.2K | |
| Non Current Liabilities Total | 6.8M | 8.1M | 450.5K | 26.4K | 10.1K | 9.6K | |
| Other Current Assets | 153.7K | 3.4M | 2.2M | 1.1M | 1.7T | 1.8T | |
| Other Stockholder Equity | 49.5M | 77.7M | 106.9M | 121.2M | 133.3T | 139.9T | |
| Short Long Term Debt Total | 5.1M | 17.2M | 4.4M | 854.7K | 301.7B | 316.7B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ensysce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.47) | Revenue Per Share | Quarterly Revenue Growth 1.531 | Return On Assets | Return On Equity |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.